Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action
about
Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart FailureMechanisms of protein-folding diseases at a glanceChemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosisThe delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiologyToward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis InhibitorsToward Optimization of the Second Aryl Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and CytotoxicityChemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasmaAromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent ConjugateTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeBifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensorsFluorogenic small molecules requiring reaction with a specific protein to create a fluorescent conjugate for biological imaging-what we know and what we need to learnModulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanismsPolymer supported synthesis of novel benzoxazole linked benzimidazoles under microwave conditions: in vitro evaluation of VEGFR-3 kinase inhibition activity.Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosisStructure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidosesA stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.Alternative modulation of protein-protein interactions by small moleculesInhibition of Beta-Amyloid Fibrillation by Luminescent Iridium(III) Complex ProbesBifunctional crosslinking ligands for transthyretinTargeting protein aggregation for the treatment of degenerative diseasesIdentification of Transthyretin Fibril Formation Inhibitors Using Structure-Based Virtual Screening.A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases.Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.Quantification of transthyretin kinetic stability in human plasma using subunit exchange.The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease.Combating neurodegenerative disease with chemical probes and model systems.Novel pharmacotherapies for cardiac amyloidosis.Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.Photophysical properties of hydroxyphenyl benzazoles and their applications as fluorescent probes to study local environment in DNA, protein and lipid.Amphiphilic copolymers reduce aggregation of unfolded lysozyme more effectively than polyethylene glycol.Current and future treatment of amyloid diseases.Nickel-Catalyzed Aromatic C-H Functionalization.
P2860
Q26776120-15D98A65-5766-4354-AFA2-ABE2B6834793Q27003095-E64D32D7-08F1-429A-A13E-AE0A2D49E3EDQ27004511-402E1FD0-EC93-4728-8C30-FC28A403E251Q27015793-9C4242E7-7903-42F8-B432-895A7E23B20CQ27652272-3851F87C-7D94-4F76-BCAC-C2AED3D52408Q27653350-896D3BE4-B471-43C3-948A-0232F2822B48Q27653642-90D6E9EB-FD37-4811-968B-DC841744F499Q27658823-4B5C0499-A026-4467-AED5-DFD06D3E4630Q27659009-033A83A1-BD16-4180-9BA9-13628ADF0729Q27675997-B5409B42-86D2-4039-A90D-F8B7E32C88C2Q27679360-091CC776-EC34-4662-803A-EA30DE4560F1Q27679824-8A6F874B-63E2-4204-B0BE-112FB13D62B5Q27680199-60460CB6-110C-4A67-987B-1134380A8EB0Q28259424-FCE18382-15FB-43AC-AD80-524072D02961Q33809558-F9BE497E-9473-4B8F-8AC9-E4B60FD8AEFAQ34078348-AFE58E44-682A-4195-921B-03C746F28612Q34096983-6D6C6FC1-1B01-4F33-8F73-B7E1F7E05FE7Q34300151-728AF96C-1E99-4769-AF2F-1EC99B7B471BQ34428314-8F450EA1-FA95-4B7E-ADF5-795A2EB483F8Q34576022-46870105-5321-4DB2-AC76-009C26ACAA4FQ34581917-BC23CCBD-5DF4-46F4-A3AA-40B1CCF169EBQ35620999-6247A9EA-B943-42B6-8133-E1FB6FFEDDF4Q36106553-E6F49224-86F6-425D-990E-0A67683EFE23Q36122263-E631FDD8-096D-4B8E-9714-0FB31D9F570AQ36235980-8673DD5B-8FF7-4BC5-81CE-44A50EEBE2E7Q36350679-1E7A6DA1-4B09-428F-A932-D1185F5FFF9FQ37004163-6A582000-98A3-46B5-8B8F-DE78A8FA4950Q37153865-3FEDD299-8383-4EED-9F44-E32BA16F3B79Q37202287-D1CC65C5-B5D1-4B9B-8418-22F69274E2EBQ37301237-3B67F5F8-3BBE-4182-A80D-1235F4DE4CC6Q37688196-736594FA-866A-4AD9-B8AE-B29066FCEB06Q37975816-3EF88E33-76FE-483B-A1F6-67484C5B6889Q38193225-CB4647F0-7A9B-47C2-8A47-9C28F9A230A8Q38261089-C5E1EDC6-056D-4C92-B76A-245E5CFDFCEBQ38709793-F268FFB5-A50D-4549-8CF7-A4123FCA3B36Q38720600-59AB785C-4189-4309-8320-190E32EE332BQ38748181-287A90B3-2795-45DD-8A1E-B7E520E13416Q38773864-905DBD15-4FE2-41A2-AF6D-C45C5957E815Q38831388-7B45FCB6-6F4C-4E0F-805F-9364207314FFQ38940388-2107D5BD-09ED-462D-9112-AD37BF0939A3
P2860
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@ast
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@en
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@nl
type
label
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@ast
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@en
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@nl
prefLabel
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@ast
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@en
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@nl
P2093
P50
P3181
P356
P1476
Benzoxazoles as transthyretin ...... ation, and mechanism of action
@en
P2093
Hans E Purkey
Hossein Razavi
James C Sacchettini
Kyle P Chiang
Maria T A Dendle
Nilofar N Mohamedmohaideen
Satheesh K Palaninathan
Songpon Deechongkit
P304
P3181
P356
10.1002/ANIE.200351179
P407
P577
2003-06-01T00:00:00Z